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ABSTRACT 
Syndecans are a four member multifunctional family of cell surface molecules with 
diverse biological roles. Syndecan-3 (SDC3) is the largest of these, but in comparison 
to the other family members relatively little is known about this molecule. SDC3 null 
mice grow and develop normally, all be it with subtle anatomical phenotypes in the 
brain. Roles for this molecule in both neuronal and brain tissue have been identified, 
and is associated with altered satiety responses. Recent studies suggest that SDC3 
expression is not restricted to neuronal tissues and has important roles in inflammatory 
disorders such as rheumatoid arthritis, disease associated processes such as 
angiogenesis and in the facilitation of infection of dendritic cells by HIV. The purpose 
of this review article is to explore these new biological insights into SDC3 functions in 
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Introduction. 
The proteoglycans are a diverse family of molecules with multiple roles in 
development, health and disease (1). Heparan Sulphate Proteoglycans (HSPGs) form 
a subset of these, and these can be secreted extracellular matrix molecules or 
membrane associated (1). The principal families of membrane associated HSPGs are 
the gypicans and syndecans. Glypicans are distinguished from syndecans by the fact 
they are tethered to the cell membrane via glycosylphosphatidylinositol anchors. 
Syndecans (SDC) are a four member family of type 1 transmembrane proteins 
consisting of two related sub-families based on sequence homology. SDC2 and 4 form 
one family and SDC1 and 3 form the other. All syndecans have a short highly 
conserved cytoplasmic domain, a single transmembrane domain, and a larger 
extracellular core protein. Syndecan ectodomains are far less conserved between 
family members or species. However, they do possess Ser-Gly GAG attachment 
motifs usually surrounded by acidic amino acid residues. Every cell type expresses at 
least one syndecan, and roles in cell adhesion, migration, growth factor signalling, 
receptor trafficking and ion channel modulation have been identified (for reviews see 
(1-5)). Of the four family members, perhaps the least well understood is Syndecan-3 
(SDC3). Predominantly, reported roles for this molecule have been exclusively related 
to the brain and nervous system, but recent studies are revealing roles for SDC3 in 
other important biological processes such as inflammation and angiogenesis. This 
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Syndecan-3 molecular architecture. 
The syndecan-3 (N-syndecan) gene was first cloned from rat Schwann cells and was 
the third syndecan of the four member family to be identified (6, 7). It bears significant 
homology to syndecan-1, although unlike syndecan-1, it has a homologue in fish (8). 
Of the four family members, syndecan-3 (SDC3) is the largest, consisting of 442 amino 
acids in humans. In mammals, the SDC3 ectodomain contains seven potential 
glycosaminoglycan (GAG) attachment sites. Four are situated towards the N-terminus 
and the remaining three reside closer to the transmembrane domain (Figure 1A). The 
type and extent of GAG substitution on syndecan-3 is likely to be cell type and tissue 
dependent. Experiments using heparan sulphate (HS) and chondroitin sulphate (CS) 
degrading enzymes would suggest that SDC3 (at least when purified from brain tissue) 
possesses both HS and CS chains (9). HS chains consist of repeated disaccharide 
units consisting of glucuronic acid and N-acetylglucosamine and chain lengths can 
range from 50-200 disaccharides. It is synthesised via a stepwise series of enzymatic 
reactions involving multiple transferases; briefly N-acetyglucosamine within a chain 
can undergo N-sulphation followed by the epimerisation of some glucuronic acids, this 
is followed by the sequential addition of first 2-O, 6-O and 3-O sulphate groups. The 
complexity of this process means that HS chains are heterogenous in terms of 
sulphation and there is considerable evidence of HS chains having domains of high, 
intermediate and low sulphation (for review see (10), Figure 1B). CS is structurally 
distinct to HS on the basis that it is comprised of repeating disaccharide units 
consisting of glucuronic acid and n-acetylgalactosamine (Figure 1B). CS chains can 
also be sulphated although the extent and heterogeneity of this is not as great as HS. 
The majority of reported interactions between SDC3 and biologically active molecules 
are with its HS chains, and far less is understood as to the role or function of SDC3 
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CS chains. The extracellular core protein also possesses a domain rich in threonine 
and proline residues, which is characteristic of mucin-like proteins, and are potential 
sites for O-linked glycosylation (6).  
Syndecan shedding is a regulated process whereby some or all of the extracellular 
domain of the molecule is cleaved from the cell surface by the action of matrix-
metalloproteases (MMPs). Shed SDC3 has been observed in conditioned media in a 
variety of experimental systems, although the precise cleavage sites and proteases 
have yet to be confirmed (11). Predictive algorithms would suggest roles for MMP2, 9 
and 14 at multiple cleavage sites but these have not been validated experimentally 
(3). SDC3, along with the other family members, form SDS insoluble dimers and this 
self-association is mediated both by residues in the transmembrane domain, and a 
membrane proximal ERKE motif (12).  
The syndecan-3 cytoplasmic domain consists of 33 aa and in common with the rest of 
the family possesses two conserved domains (C1 and C2) flanking a variable 
sequence (V region), which is unique to each family member (Figure 1C). Syndecans 
all have the capability of interaction with PDZ proteins possessing a conserved EFYA 
motif at the C-terminus of the C2 region. Interactions between SDC3 and PDZ proteins 
such as syntenin, CASK, TIAM1, synectin and synbindin have been reported. The SY 
sequence (Ser418, Tyr419 in human SDC3, Figure 1C) in the C1 region of SDC3 is 
common to all syndecans. Studies with SDC4 have shown that phosphorylation of 
either residue is important for its functionality. Syndecans have proven remarkably 
recalcitrant to structural analysis, none more so than SDC3, for which there are no 
structural records in the databases (2). However, structural analysis of peptides 
corresponding to the syndecan-4 cytoplasmic domain in which this serine residue is 
phosphorylated show that this alters the conformation of this molecule considerably, 
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and expression phospho-mimetic mutants of this residue leads to enhanced cell 
migration (13). In other work, the Y (Tyr180 in human SDC4) was identified as a 
substrate for Src kinase and this has implications for the trafficking of integrins. It would 
not be surprising if phosphorylation of these conserved residues impacted on SDC3 
functionality in a similar fashion (14). Additionally, in vitro studies have indicated that 
the other 2 tyrosines could potentially be phosphorylated, however no functional role 
for this has been demonstrated (15). The V region of SDC3 also bears similarities to 
other syndecans in that there are 2 lysine residues (Lys425 and Lys433). Studies with 
syndecan-4 have shown the importance of these lysines for binding phospho-
inositides (PIP3) and this not only stabilises the structure of SDC4 cytoplasmic domain 
but this interaction is also associated with upregulating the activity of PKCα which 
promotes many of the downstream cell adhesion pathways associated with SDC4 (16, 
17). It is therefore also conceivable that the interactions with the SDC3 V region and 
phospho-inositides could be important for SDC3 functionality.  
Syndecan-3 in the brain and nervous tissue. 
The association with SDC3 and cells of a neuronal lineage is well established and a 
number of phenotypes associated with both the brain and nervous tissue have been 
identified (18, 19). Although no gross abnormalities are observed in the developing 
mouse brain, stereological analysis of sections revealed differences in the cellular 
density of key areas. Specifically, SDC3 null animals have a higher density of cells in 
deep cortical areas and a reduced number in the superficial cortical layers. This was 
found to be due to defects in neural cell migration during development and in particular, 
an interaction between SDC3 and heparin binding growth associated molecule 
(HBGAM) (20). Syndecans are known to be key players in cell adhesion and migration, 
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so identifying a migration defect in neural cells associated with SDC3 is entirely 
consistent. 
SDC3 is found in other tissues of the brain, immunostaining of wild-type mice revealed 
SDC3 to be expressed in the hypothalamus, particularly in the paraventricular nucleus 
and the lateral hypothalamic area (21). SDC3 expression (uniquely amongst the family 
members) is upregulated in the hypothalamus in response to food deprivation and the 
situation is reversible once starved animals are refed. Unsurprisingly, food deprived 
animals exhibit an abnormal desire for food once the deprivation is ended. However, 
this response is lacking in animals null for SDC3, suggesting a role for SDC3 in feeding 
behaviours (21). This is further evidenced by the fact that SDC3 animals are partially 
resistant to obesity when given a high fat diet due to reduced food intake (22). 
Several hypothalamic neuropeptides regulate feeding behaviours; for example, 
agouti-related protein (AgRP), melanin concentrating hormone (MCH) and 
neuropeptide Y stimulate increased feeding behaviours, whereas α-melanocyte 
stimulating hormone (αMSH) and corticotrophin releasing hormone (CRH) serve to 
inhibit pathways associated with increased feeding (23). It is known that many of the 
interactions between these peptides and their receptors at least in part has an HS 
involvement. There is a complex interplay between these neuropeptides and SDC3 is 
thought to have a role in promoting the antagonism between AgRP and αMSH for the 
melanocortin receptor MC-4R (24, 25). In essence, when animals are starved, SDC3 
is upregulated and this promotes the binding of AgRP to MC-4R leading to a reduction 
in anti-satiety signals, and enhanced feeding. In animals null for SDC3, this interaction 
does not occur meaning αMSH is free to bind MC-4R leading to a reduction in the 
desire to feed in these animals. Interestingly, another consequence of starving is an 
upregulation of Tissue Inhibitor Metalloprotease‐3 (TIMP3), this acts as an inhibitor to 
7 
 
Arokiasamy et al 2019 
a variety of MMPs which also have key roles in syndecan shedding. This provides a 
means of regulating feeding behaviours since under conditions of starvation, SDC3 
shedding is inhibited thus promoting occupation of MC-4R by AgRP and promoting 
feeding. On the other hand,  under feeding conditions TIMP is down regulated, SDC3 
shedding is up regulated and the satiety signal through the αMSH/MC-4R axis is 
promoted (26, 27). The hypothalamus also has key roles in modulating reward 
processing in addictive behaviours and SDC3 also has a role to play in these. Cocaine 
administration increases SDC3 expression in the lateral hypothalamic area and SDC3 
knockout mice actually exhibit more addictive behaviours than wild-type counterparts. 
SDC3 null animals were more susceptible to cocaine addiction - a situation that could 
be reversed upon re-expression of SDC3. Glial cell line-derived growth factor (GDNF) 
acts to both increase and decrease cocaine self-administration behaviours in rodents 
through its interactions with a signalling complex consisting of the receptor GFR-α1 
and the tyrosine kinase c-Ret (28). SDC3 is thought to disrupt this signalling complex 
since it can also bind GDNF and as such, is a potentially important target for treating 
addictions.  
Syndecan-3 in disease. 
It is very evident from the studies described above that SDC3 plays a critical role in 
both brain development and behaviour. However, other roles for SDC3 on endothelial 
cells (ECs) and leukocytes are emerging in inflammatory responses. The purpose of 
the remainder of the review is to examine the roles of SDC3 in the context of 
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Syndecan-3 in rheumatoid arthritis. 
SDC3 is expressed on endothelia in both rheumatoid and non-rheumatoid synovia and 
is thought to have roles in binding chemokines, specifically CXCL8, during the 
progression of the disease (29, 30). Interestingly, mice null for SDC3 are protected in 
a model of antigen-induced arthritis (methylated BSA induced), in which clinical 
scores, leukocyte recruitment and cartilage damage were all significantly less than 
wild-type animals (31). This is a common feature of syndecan null animals, in that 
phenotypes only emerge when the animals are challenged and more often than not, 
deletion of syndecans leads to less severe disease progression, suggesting a role only 
in pathological scenarios. This study also highlighted a slight paradox; in models of 
both dermal and cremasteric inflammation, leukocyte rolling and adhesion was 
elevated in SDC3-null mice, suggesting an anti-inflammatory role for this molecule 
(31). This therefore suggests distinct roles for SDC3 depending on the vascular bed. 
SDC3 is thought to facilitate chemokine interactions via binding to its GAG chains, and 
it is likely that the extent and sulphation pattern of the HS chains in ECs from different 
tissues will vary. Administration of recombinant forms of SDC3 ectodomains, 
expressed in mammalian cells, have also been used in both collagen- and methylated 
BSA-induced murine inflammatory arthritis models with efficacious effects indicating 
both the therapeutic potential of targeting this molecule but also the importance of 
shed SDC3 in disease progression (32).   
Syndecan-3 in neovascular diseases. 
Angiogenesis, the formation of new blood vessels from existing vasculature, and 
inflammation are intrinsically linked. SDC3-null mice exhibit no gross abnormalities 
suggesting that the formation of the vasculature in these animals is normal. However, 
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in-depth studies on parameters such as vessel density, vessel diameter, vessel 
frequency and pericyte coverage have yet to be undertaken. SDC3 is expressed on 
ECs in early retinal development in rats (33), and has been found expressed on ECs 
from a variety of tissues. For example, along with SDC4, SDC3 is abundant on cultured 
human umbilical vein ECs (34), and human coronary artery endothelial cells as well 
as human coronary artery smooth muscle cells (35). Vascular endothelial growth factor 
A (VEGFA), alongside a number of other proangiogenic factors are known to bind HS 
(36, 37), so it would be tempting to propose a role for SDC3 in this context. 
Interestingly, sequences within the SDC3 extracellular core protein exert anti-
angiogenic affects by blocking EC migration (38). A fusion protein consisting of GST 
fused to the N-terminus of the SDC3 ectodomain inhibits angiogenic sprout formation 
from aortic explants, and also inhibited EC micro-capillary formation and EC migration. 
Importantly, this protein was generated in a prokaryotic expression system so lacked 
any GAG substitutions, indicating that this is an intrinsic property of the core protein 
(38). This is also in common with other syndecan family members, whose core 
proteins also exhibit biological activity (39). SDC1, which is closely related to SDC3, 
has anti-angiogenic sequences within its core protein but they bear no homology to 
the SDC3 sequence suggesting that the anti-angiogenic properties of the latter may 
work via a distinct mechanism (40, 41). It remains unclear how these sequences affect 
the biology of the full length molecule - do they bind receptors in cis, as is the case for 
SDC1 (41)  or in trans when shed as is the case for SDC2 (42)? 
A key step in the formation of new blood vessels, and indeed inflammation, is the 
disassembly of EC junctions, enabling both the migration and proliferation of ECs and 
vascular leakage during disease. Thrombin-cleaved fragments of the SDC3 (and 
SDC4) ectodomain have been shown to promote this process in the human lung 
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microvasculature, which has ramifications for conditions such as sepsis or thrombotic 
disease states, where thrombin is activated (43).  This would suggest opposing roles 
for the SDC3 ectodomain in angiogenesis; on the one hand, studies would suggest 
that the core protein independent of GAG chains can inhibit the process (44), whereas 
fragments of SDC3 cleaved from mammalian cells with their GAGs intact appear to 
promote vascular permeability and EC migration. It is conceivable that since the 
thrombin cleavage sites in the SDC3 extracellular core proteins are not known, smaller 
fragments of the mature protein may in fact exhibit pro-angiogenic effects (Figure 2).  
Syndecan-3 interactions with Human Immunodeficiency Virus 1 (HIV-1) 
Dendritic cells (DCs) are antigen presenting cells and play a critical role in identifying 
and capturing pathogens in peripheral tissues and subsequently priming T cells in the 
lymph nodes to initiate adaptive immune responses. Sexual transmission is the main 
route of HIV-1 dissemination and in the absence of surface lesions, the genital 
epithelia presents a barrier to viral crossing (45, 46). HIV circumvents this by using 
DCs as molecular Trojan horses to cross this normally impenetrable epithelium (47). 
DCs induce virus-specific CD8+ T cell responses by presenting antigens bound by 
major histocompatibility complex molecules class-I (MHC-I) to these T cells, thus 
activating them. DCs infected with viruses can use viral proteins which are 
endogenously synthesised from viral replication as antigens for presentation on MHC-
I in a process commonly called direct presentation (48). On the other hand, DCs not 
infected with viruses must engulf exogenous viral antigens for presentation to CD8+ T 
cells via a process known as cross-presentation (49). DCs have been shown to be 
susceptible to HIV-1 infection (50). Therefore, direct presentation usually takes place 
in the context of normal HIV transmission.   
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A number of cell surface receptors have been implicated in facilitating both the 
recognition, binding and transmission of the HIV-1 virus; different receptors have been 
shown to interact with HIV-1 on DCs, such as the C-type lectin DC-SIGN (51, 52), the 
mannose receptor (53), langerin (54), and CD4 (53). Most of these studies were 
carried out using HIV-1 glycoprotein gp120 but other experiments using HIV-1 
particles suggest that other unknown receptors are also involved (55). 
DC-SIGN, which binds with high affinity to ICAM-3 present on resting T cells, was 
discovered to play a key-role in the dissemination of HIV-1 by DCs (51, 56). It does 
not function as a receptor for HIV-1 virus entry into DCs but instead promotes efficient 
capture of HIV-1 viruses in the periphery and facilitate their transport to secondary 
lymphoid tissues to enhance infection in trans of cells that express CD4 and 
chemokine receptors (i.e. T cells) (51). More recently, Lotte et al. (57) found SDC3 to 
be highly expressed by DCs, namely immature monocyte-derived DCs, and was 
identified as a major specific HIV-1 attachment receptor. SDC3 captures HIV-1 
through interaction with its HS chains and the viral envelope protein gp120; it also acts 
to stabilise the captured virus, enhance DC infection and like DC-SIGN, promotes HIV 
transmission to T cells. The authors also found that neutralisation of both SDC3 and 
DC-SIGN leads to the complete impairment of HIV-1 binding to DCs and transmission 
to T cells. Neutralisation of SDC3 alone led to partial inhibition of HIV-1 transmission. 
As current anti-viral treatments are only aimed at blocking viral replication in T-cells, 
this opens up a whole new avenue in terms of developing an HIV microbicide that 
targets DC-SIGN and SDC3 on DCs.  
Interestingly, HIV-1 infected individuals known as HIV controllers (HICs) who are able 
to control viral replication without anti-retroviral therapy exist, but are rare. DCs from 
these individuals express higher levels of SDC3 and DC-SIGN and have been shown 
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to be less susceptible to HIV-1 infection than cells from healthy donors. On the 
contrary, DCs from HICs show an enhanced capacity to capture HIV-1 when 
compared to cells from healthy donors or HIV-1 patients currently on anti-retroviral 
treatment with suppressed viral load (58). High levels of both SDC3 and DC-SIGN on 
DCs have previously been confirmed to play crucial roles in facilitating HIV-1 capture 
and this would, at first, seem contradictory (51, 56, 57). However, the combination of 
being less permissible to HIV-1 infection and having increased capacity to capture 
HIV-1 particles may allow DCs from HICs to preserve their function from the 
deleterious effect of infection – all of which might facilitate the induction of HIV-specific 
CD8+ T cells by cross-presentation in the context of low viremia. 
Concluding Remarks 
In this review, we have explored the diverse roles that the HSPG, SDC3, plays in a 
range of disease and developmental contexts. Although many phenotypes have been 
described, there is still a great deal to learn about how SDC3 is actually functioning in 
these scenarios. SDC1, 2 and 4 have been intrinsically linked with integrins and in 
particular modulating cell adhesion and migration responses. SDC1 has been shown 
to modulate the activity of a number of αV integrin heterodimers, as has SDC4 (14, 
59). Similarly β1 integrin heterodimers have also been associated with SDC2 and 4 
(14, 42, 60). The consequences of these interactions lead to cell migration and 
adhesion defects when they are compromised. Based on this, it seems likely that 
SDC3 would also interact and/or modulate integrin activity although further research 
is required to establish this for sure.  
In many instances, it is interactions with SDC3 HS chains that appear to be driving the 
biological effects observed, whether it be acting to bind neuropeptides, inflammatory 
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mediators or viral particles. However, this does raise the question as to what is driving 
this selectivity of the molecules towards SDC3 HS. In many cases, the other 
syndecans and indeed glypican family members are present in abundance but cannot 
perform the same functions as SDC3 despite possessing HS chains. One possibility 
is that sequences specific to SDC3 may influence the type and nature of GAG 
substitution, and it is this that differentiates SDC3 from other HSPGs. This would not 
be without precedent since studies have shown that sequences in the SDC2 
ectodomain can influence the sulphation pattern of SDC2 HS (61). Alternatively, it 
could be that the expression and localisation of SDC3 in cells could be more 
exquisitely regulated than first thought. Studies in the brain have shown that SDC3 
expression can be induced both by starvation and narcotic substances and this is not 
the case for other family members. SDC3-null animals (like the other family members) 
develop normally for the most part and it is when challenged that phenotypes are 
observed. This is suggestive that SDC3 expression is governed by factors associated 
with these challenges. Molecules such as this make tempting therapeutic targets since 
it is to be expected that off-target effects would be negligible since the molecule is only 
having a role in the disease state. It is also entirely possible this selectivity of function 
of SDC3 HS is actually a combination of both of the above.  
The studies described above point to important roles for SDC3 in inflammatory disease 
which require further investigation and hint that this molecule is important not just in 
the neuronal context but in other tissues. More detailed studies are required in both 
the SDC3 null mouse, and patient samples, to explore disease models where 
inflammation and angiogenesis are a feature. Greater mechanistic insight is required 
to understand how SDC3 exerts its functions. It remains a possibility that modulating 
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SDC3 function could prove useful in the treatment of the pathologies described above, 
however, the means by which this could be achieved requires elucidating.  
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Figure 1:  
 
 
Schematic diagram and features of SDC3. (A) Human SDC3 is 442aa in length and 
contains 7 potential sites for GAG substitution. Most functions ascribed to SDC3 relate 
to interactions through its HS chains. HS chains are heterogenous in nature and 
contain regions of low, intermediate and high sulphation. (B) Structure of HS and CS. 
(C) The cytoplasmic domain of SDC3 is 33 amino acids in length and shares 
conserved C1 and C2 domains with other syndecan family members. The C-terminal 
PDZ binding domain is indicated by a dashed black box. Potential sites of tyrosine 
phosphorylation are indicated by arrows and lysine residues potentially involved in 
phosphoinositide binding are indicated by asterisks. The conserved SY in the C1 
domain, which when phosphorylated in other syndecan family members impact on 
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Figure 2: 
 
Contrasting roles for the SDC3 ectodomain in angiogenesis. (A) Thrombin 
cleaved fragments of the SDC3 ectodomain promote pro-angiogenic processes such 
as EC junctional disassembly (43). (B) Full length bacterially expressed SDC3 
extracellular core protein fused at the N-terminus to GST inhibits angiogenesis in a 
number of in vitro and ex-vivo models (38). Since the thrombin cleavage sites of SDC3 
are not known it is possible that one or more of the cleavage products is pro-
angiogenic whereas the full length sequence acts to inhibit new blood vessel 
formation. 
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